Developing vaccine against pathogenic streptococcus

Smooth Drug Development is developing a novel vaccine against pathogenic streptococcus. 

Phase I studies are conducted when the drug has shown efficacy and safety studies. Usually these studies are conducted in healthy volunteers, however, toxic agents are tested in patients with relevant diseases. In phase I safety, pharmacokinetic and pharmacodynamic parameters are tested. Sometimes these studies are divided into research phase Ia and Ib according to the primary target.

Smooth Drug Development is a well-established Contract Research Organization (CRO) conducting clinical trials in Russia, CIS and Baltic States since 2011.